Researchers at Vanderbilt University Medical Center and Case Western Reserve University in Cleveland have been awarded a five-year, $3.3 million grant by the National Cancer Institute to apply artificial intelligence (AI) to help customize treatment for oral cancer patients.

Treatment with convalescent plasma vastly improved the survival rate of patients hospitalized for COVID-19 who also had hematologic malignances that compromise the immune system, according to new data released by the COVID-19 and Cancer Consortium (CCC19).

After a recent study showed that chronic lymphocytic leukemia patients who received ibrutinib as a frontline treatment had a 7% death rate, a new study offers a clearer picture on the reasons for the deaths.

Vivian Weiss, MD, PhD, has been named a 2020 V Scholar and will receive $200,000 from the V Foundation for Cancer Research.

Combining immunotherapy and radiation therapy may be a powerful treatment approach for castration-resistant prostate cancer.

Michael Savona, MD, professor of Medicine and Cancer Biology, and director of Hematology Research at Vanderbilt-Ingram Cancer Center, has received a competitive grant award from the Edward P. Evans Foundation.

Researchers are chronicling rare but serious toxicities that may occur with immune checkpoint inhibitors, the most widely prescribed class of immunotherapies.

The nature of childhood cancer is different than adult cancer, and so is the approach to treatment.

Patients who received atezolizumab in addition to standard chemotherapy lived two months longer than those treated with chemotherapy alone, according to a recent study published in the New England Journal of Medicine.

Cancer investigators led by researchers at Vanderbilt-Ingram Cancer Center have co-developed a liquid biopsy blood-based assay used to identify specific gene mutations associated with the development or relapse of small-cell lung cancer (SCLC)